title: [The role of disturbances of lipid metabolism in pathogenesis of allergic rhinitis].
abstract: Physiological normal levels of total cholesterol, total lipids, total protein, superoxide dismutase, catalase, malonic dialdehyde, and total antioxidant activity were determined for the first time in nasal secretion of volunteer donors (n = 24). Excessive lipid peroxidation and suppression of antioxidant protection system were documented in 70 patients with round-the-year allergic rhinitis of whom 26 and 44 presented with the mild and moderately forms of the disease, respectively. The clinical efficiency of polyoxidonium (Russia) in the treatment of allergic rhinitis has been demonstrated. This preparation reduces the intensity of lipid peroxidation and strengthens the antioxidant protection of the organism. The results of the study confirm the high efficacy of combined therapy of allergic rhinitis with aerius and polyoxidonium.
authors.forename: G A
authors.initials: GA
authors.lastname: Gadzhimirzaev
authors.forename: Z T
authors.initials: ZT
authors.lastname: Mikhrailova
authors.forename: I G
authors.initials: IG
authors.lastname: Akhmedov
authors.forename: G R
authors.initials: GR
authors.lastname: Muradova
mesh_terms: D000293:Adolescent; D000328:Adult; D004333:Drug Administration Routes; D004359:Drug Therapy, Combination; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects; D050356:Lipid Metabolism / Q000187:drug effects; D017336:Loratadine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009093:Mucus / Q000187:drug effects / Q000378:metabolism; D009297:Nasal Mucosa / Q000187:drug effects / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D011108:Polymers / Q000008:administration & dosage / Q000009:adverse effects; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D012720:Severity of Illness Index; D013482:Superoxide Dismutase / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D039563:Histamine H1 Antagonists, Non-Sedating; D007155:Immunologic Factors; D010879:Piperazines; D011108:Polymers; D008315:Malondialdehyde; D017336:Loratadine; C540909:azoximer bromide; D013482:Superoxide Dismutase; C121345:desloratadine